Category Archives: Parkinson’s Treatment

Where does Parkinsons disease (PD) begin? In the brain or in the gut? According to new findings, both are possibilities Continue reading →

27 Nov 2019 Twenty years ago, researchers took fibroblasts from the skin of eight Alzheimers patients, engineered them to produce nerve-growth factor, and slid them into each volunteers basal forebrain. They hoped the neurotrophin would halt or slow the neurodegeneration that robbed them of their memories, indeed their lives. Continue reading →

The Parkinsons Disease Treatment Market report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Continue reading →

SAN DIEGO--(BUSINESS WIRE)-- - ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. Continue reading →

Parkinson's disease is caused by loss of nerve cells in part of the brain called the substantia nigra, which leads to a reduction in a chemical called dopamine in the brain. Dopamine plays a vital role regulating the movement of the body so a loss of this chemical can cause movement problems. As the condition progresses, the symptoms of Parkinson's disease can get worse and it can become increasingly difficult to carry out everyday activities without help so it is important to recognise the early warning signs to maintain quality of life for as long as possible Continue reading →

Some diseases of the brain are incredibly hard to treat. Parkinsons Disease. Alzheimers Continue reading →

Dog and medical enthusiasts gathered to support and learn more about PADs for Parkinsons. The nonprofit that trains dogs to sniff out Parkinsons Disease held a fundraising and outreach presentation on Nov. 16 at Brickworks Continue reading →

Tiny and traceable man-made crystals, known as quantum dots, may be useful in carrying toxins to select cells in the brain, allowing researchers to better understand Parkinsons neurodegenerative processes by being able to model and visualize them, researchers in Canada report. Their study, Quantum dot conjugated saporin activates microglia and induces selective substantia nigra degeneration, was published in NeuroToxicology Continue reading →

Global Parkinsons Disease Treatments Market 2019 2026 Report gives an overview of the related market involving types, applications and key manufacturers with characteristics, technology and market chain with analysis and recent market trends and development. The report has opinions from industry experts and offers an outline of the past years and the current market situation. Continue reading →

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced today that the U.S. Food and Drug Administration (FDA) has granted the Rare Pediatric Disease designation for sarizotan, the companys product candidate for the treatment of Rett syndrome, a rare neurodevelopmental disorder primarily affecting females, with no approved treatments currently available. Continue reading →